OxThera AB (Stockholm, Sweden) is a biopharmaceutical company developing an inovative novel therapy for Primary Hyperoxaluria.
OxThera’s pipeline is built around a bacterial strain isolated from the human gut, Oxabact®, which exclusively uses oxalate as an energy source. Administration of the bacteria at pharmacological doses to patients promotes active secretion of oxalate into the gut where it is subjected to degradation and elimination. This innovative approach is reducing the high oxalate burden on the kidneys, potentially preventing disease progression.
Oxabact® is in late-stage clinical development in Primary Hyperoxaluria.
Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of Primary Hyperoxaluria.
For more information, please contact:
Phone: +45 2481 6967